Tumors may modulate host immunity partly through hypoxia-induced sympathetic bias

Medical Hypotheses

Volumn 63, Issue 2, 2004, Pages 352-356

  Joon Yun, A ^a   Bazar, Kimberly A ^b   Lee, Patrick Y ^a  

^a STANFORD UNIVERSITY   (United States)

^b San Mateo County Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYGEN;

ADAPTATION; ADRENERGIC ACTIVITY; BIOLOGY; CANCER; CANCER RISK; CHEMORECEPTOR; DEPLETION; GLYCOLYSIS; HUMAN; HYPOXIA; IMMUNE RESPONSE; IMMUNITY; IMMUNOREGULATION; MICROENVIRONMENT; NEOVASCULARIZATION (PATHOLOGY); OXYGEN CONSUMPTION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SURVIVAL; SYMPATHETIC FUNCTION; TH1 CELL; TH2 CELL; TRANSCRIPTION REGULATION; TUMOR; TUMOR GROWTH; TUMOR IMMUNOLOGY; TUMOR VASCULARIZATION;

EID: 3242811307     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.02.026     Document Type: Article

References (56)

1. Vaupel P., Thews O., Hoeckel M. Treatment resistance of solid tumours: role of hypoxia and anemia. Med. Oncol. 18(4):2001;243-259
2. Carmeliet P., Dor Y., Herbert J.-M., et al. Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394(6692):1998;485-490
3. Wang G.L., Semenza G.L. Purification and characterisation of hypoxia-inducible factor-1. J. Biol. Chem. 270(3):1995;1230-1237
4. Salceda S., Caro J. Hypoxia-inducible factor-1HIF-1 protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. J. Biol. Chem. 272(36):1997;22642-22647
5. Huang L.E., Arany Z., Livingston D.M., Bunn H.F. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its subunit. J. Biol. Chem. 271(50):1996;32252-32259
6. ′ to the human erythropoietin gene Proc. Natl. Acad. Sci. USA. 88(13):1991;5680-5684
7. Koshikawa N., Iyozumi A., Gassmann M., Takenaga K. Constitutive upregulation of hypoxia-inducible factor-1alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure. Oncogene. 22(43):2003;6717-6724
8. 2 in muscle cells in culture. Am. J. Physiol. 262(3 Pt 1):1992;C682-C690
9. Melillo G., Taylor L.S., Brooks A., Musso T., Cox G.W., Varesio L. Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine. J. Biol. Chem. 272(18):1997;12236-12243
10. Ryan H.E., Lo J., Johnson R.S. HIF-1 is required for solid tumour formation and embryonic vascularisation. EMBO J. 17(11):1998;3005-3015
11. Blancher C., Moore J.W., Talks K.L., Houlbrook S., Harris A.L. Relationship of hypoxia-inducible factor (HIF)-1α and HIF-2α expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 60(24):2000;7106-7113
12. Kim C.Y., Tsai M.H., Osmanian C., et al. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low oxygen conditions. Cancer Res. 57(19):1997;4200-4204
13. Bachtiary B., Schindl M., Potter R., et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin. Cancer Res. 9(6):2003;2234-2240
14. Giatromanolaki A., Sivridis E., Kouskoukis C., Gatter K.C., Harris A.L., Koukourakis M.I. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res. 13(5):2003;493-501
15. Kurokawa T., Miyamoto M., Kato K., et al. Overexpression of hypoxia-inducible-factor 1alpha (HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br. J. Cancer. 89(6):2003;1042-1047
16. Höckel M., Vorndran B., Schlenger K., Baussmann E., Knapstein P.G. Tumour oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol. Oncol. 51(2):1993;141-149
17. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157(2):2000;411-421
18. Teicher B.A., Lazo J.S., Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumour cells. Cancer Res. 41(1):1981;73-81
19. Teicher B.A. Hypoxia and drug-resistance. Cancer Metast. Rev. 13(2):1994;139-168
20. Teicher B.A., Holden S.A., Jacobs J.L. Approaches to defining the mechanism of enhancement by Fluosol-DA20% with carbogen of melphalan anti-tumour activity. Cancer Res. 47(2):1987;513-518
21. Ebert M.P., Günther T., Hoffmann J., et al. Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer. Cancer Res. 60(7):2000;1995-2001
22. Fardel O., Locureur V., Guilllouzo A. The. P -glycoprotein multidrug transporter Gen. Pharmacol. 27(8):1996;1283-1291
23. Gray L.H., Conger A.D., Ebert M., Hornsey S., Scott O.C. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26(312):1953;638-648
24. Narkiewicz K., van P.J., Narkiewicz de Borne, C.A. Pesek,, et al. Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation. 99(9):1999;1183-1189
25. Somers V.K., Zvala D.C., Mark A.L., Abboud F.M. Influence of ventilation and hypocapnia on sympathetic nerve responses to hypoxia in normal humans. J. Appl. Physiol. 67(5):1989;2095-2100
26. Ponikowski P., Chua T.P., Piepoli M., et al. Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. Circulation. 96(8):1997;2586-2594
27. Somers V.K., Dyken M.E., Clary M.P., Abboud F.M. Sympathetic neural mechanisms in obstructive sleep apnea. J. Clin. Invest. 96(4):1995;1897-1904
28. Weihe E., Nohr D., Michel S., et al. Molecular anatomy of the neuro-immune connection. Int. J. Neurosci. 59(1-3):1991;1-23
29. Felten S.Y., Felten D.L., Bellinger D.L., et al. Noradrenergic sympathetic innervation of lymphoid organs. Prog. Allergy. 43:1988;14-36
30. Ernst P.B., Song F., Klimpel G.R., et al. Regulation of the mucosal immune response. Am. J. Trop. Med. Hyg. 60(4 Suppl):1999;2-9
31. Elenkov I.J., Papanicolaou D.A., Wilder R.L., Chrousos G.P. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: Clinical implications. Proc. Assoc. Am. Physicians. 108(5):1996;374-381
32. van derPoll T., Coyle S.M., Barbosa K., Braxton C.C., Lowry S.F. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J. Clin. Invest. 97(3):1996;713-719
33. Suberville S., Bellocq A., Fouqueray B., Philippe C., Lantz O., Perez J., et al. Regulation of interleukin-10 production by beta-adrenergic agonists. Eur. J. Immunol. 26(11):1996;2601-2605
34. Panina-Bordignon P., Mazzeo D., Lucia P.D., et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J. Clin. Invest. 100(6):1997;1513-1519
35. Elenkov I.J., Wilder R.L., Chrousos G.P., Vizi E.S. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 52(4):2000;595-638
36. Lorton D., Lubahn C., Bellinger D.L. Potential use of drugs that target neural-immune pathways in the treatment of rheumatoid arthritis and other autoimmune diseases. Curr. Drug Targets Inflamm. Allergy. 2(1):2003;1-30
37. Leussink V.I., Jung S., Merschdorf U., Toyka K.V., Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch. Neurol. 58(1):2001;91-97
38. Elenkov I.J., Chrousos G.P. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann. NY Acad. Sci. 966:2002;290-303
39. Hassig A., Kremer H., Liang W.X., Stampfli K. The role of the Th-1 to Th-2 shift of the cytokine profiles of CD4 helper cells in the pathogenesis of autoimmune and hypercatabolic diseases. Med. Hypotheses. 51(1):1998;59-63
40. Wei H., Sun R., Xiao W., et al. Traditional Chinese medicine Astragalus reverses predominance of Th2 cytokines and their up-stream transcript factors in lung cancer patients. Oncol. Rep. 10(5):2003;1507-1512
41. Luo Y., Chen X., O'Donnell M.A. Role of Th1and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine. 21(1):2003;17-26
42. Ardestani S.K., Inserra P., Solkoff D., Watson R.R. The role of cytokines and chemokines on tumor progression: a review. Cancer Detect. Prev. 23(3):1999;215-225
43. Yamazaki K., Yano T., Kameyama T., Suemitsu R., Yoshino I., Sugio K. Clinical significance of serum TH1/TH2 cytokines in patients with pulmonary adenocarcinoma. Surgery. 131(1 Suppl):2002;S236-S241
44. Shibata M., Nezu T., Kanou H., Abe H., Takekawa M., Fukuzawa M. Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J. Clin. Gastroenterol. 34(4):2002;416-420
45. Lauerova L., Dusek L., Simickova M., et al. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma. 49(3):2002;159-166
46. Psarra J., Kapsimali A., Mantzana V., et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sezary syndrome. Br. J. Dermatol. 148(4):2003;709-718
47. Elgert K.D., Alleva D.G., Mullins D.W. Tumor-induced immune dysfunction: the macrophage connection. J. Leukocyte Biol. 64(3):1998;275-290
48. 2 gradients in solid tumours in vivo high-resolution measurements reveal a lack of correlation. Nat. Med. 3(2):1997;177-182
49. Warburg O. On the origin of cancer cells. Science. 123(3191):1956;309-314
50. Schmaltz C., Hardenbergh P.H., Wells A., Fisher D.E. Regulation of proliferation-survival decisions during tumour cell hypoxia. Mol. Cell Biol. 18(5):1998;2845-2854
51. Vaupel P., Schaefer C., Okunieff P. Intracellular acidosis in murine fibrosarcomas coincides with ATP depletion, hypoxia, and high levels of lactate and total Pi. NMR Biomed. 7(3):1994;128-136
52. Wykoff C.C., Beasley N.J.P., Watson P.H., et al. Hypoxia-inducible expression of associated-associated carbonic carbonic anhydrase IX, in invasive breast carcinoma. Cancer Res. 60(24):2000;7075-7083
53. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2(1):2002;38-47
54. Offner B., Czachurski J., Konig S.A., Seller H. Different effects of respiratory and metabolic acidosis on preganglionic sympathetic nerve activity. J. Appl. Physiol. 77(1):1994;173-178
55. Varterasian M., Meyer M., Fingert H., et al. Baseline Heart Rate-Corrected QT and Eligibility for Clinical Trials in Oncology. J. Clin. Oncol. 21(17):2003;3378-3379
56. K Esposito, Marfella R R., Gualdiero P., et al. Sympathovagal Balance, Nighttime Blood Pressure, and QT Intervals in Normotensive Obese Women. Obes. Res. 11(5):2003;653-659